Norbert Pescosta

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

Michèle Cavo, Paola Tacchetti, Francesca Patriarca et al. · The Lancet · 2010 · 820 citations

Medicine, Hematology, Pharmacotherapy +17

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

Antonio Palumbo, Michèle Cavo, Elena Zamagni et al. · Journal of Clinical Oncology · 2011 · 322 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Francesca Gay, Stefania Oliva, Maria Teresa Petrucci et al. · The Lancet Oncology · 2015 · 313 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.

Gino Santini, Luigi Salvagno, Pietro Leoni et al. · Journal of Clinical Oncology · 1998 · 207 citations

Medicine, Hematology, Oncology +14

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

Antonio Palumbo, Maria Teresa Ambrosini, Giulia Benevolo et al. · Blood · 2006 · 181 citations · Full text

Medicine, Hematology, Oncology +12